

JONAS CENTER CELLULAR THERAPY SYMPOSIUM

PHYSICIAN CREDIT: The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of **5.25 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER HEALTH PROFESSIONAL CREDIT

Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for **AMA PRA Category 1 Credit™** from organizations accredited by the ACCME, please consult your professional licensing board.

REGISTRATION

Early registration ends August 5, 2022

PHYSICIAN & ACADEMIC RESEARCHERS


Early In-Person Registration:	\$140
Regular In-Person Registration:	\$175
Virtual Only:	\$105

OTHER HEALTHCARE PROFESSIONAL

Early In-Person Registration:	\$95
Regular In-Person Registration:	\$145
Virtual Only:	\$85

TRAINEES:

Regular In-Person Registration:	\$60
Virtual Only:	\$36



AT THE FOREFRONT

**UChicago
Medicine**

The University of Chicago
Center for Continuing
Medical Education
5841 S. Maryland Ave., MC 1137
Chicago, IL 60637

Follow us on Twitter:

@UChicagoCME



FOR MORE INFORMATION & TO REGISTER:
cme.uchicago.edu/JCCTS2022

QUESTIONS? Contact Meeting Achievements:
219.465.1115 or by email at
support@meetingachievements.com

JONAS CENTER CELLULAR THERAPY SYMPOSIUM

2022

This conference will highlight basic and translational research advances in the field of cellular therapy for hematologic malignancies, solid tumors, and non-oncologic conditions.

REGISTER TODAY!

SEPTEMBER 16, 2022

HYBRID FORMAT: ONLINE & IN-PERSON
THE DAVID RUBENSTEIN FORUM, CHICAGO, IL



AT THE FOREFRONT

**UChicago
Medicine**

David and Etta Jonas
Center for Cellular
Therapy

TARGET AUDIENCE

This activity is designed for basic and translational researchers, medical oncologists and oncology fellows, research fellows, immunologists, and healthcare professionals interested in tumor immunology and cellular immunotherapy.

FOR MORE INFORMATION

cme.uchicago.edu/JCCTS2022

COURSE DESCRIPTION

Adoptive immunotherapy has shown encouraging results in the treatment of select hematologic malignancies and has the promise to also be applied to a wider range of diseases. This conference will highlight basic and translational research advances in the field of cellular therapy for hematologic malignancies, solid tumors, and non-oncologic conditions.

COURSE DIRECTOR

Peter Riedell, MD

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Identify current applications of CAR T-cell therapy in hematologic malignancies;
2. Describe pre-clinical and clinical cellular therapy manufacturing processes;
3. Discuss novel manufacturing techniques including point-of-care cellular therapy manufacturing;
4. List mechanisms of relapse/resistance to cellular therapy;
5. Evaluate strategies to overcome resistance to cellular therapy treatment approaches;
6. Describe current approaches and challenges using cellular therapy in patients with solid tumor malignancies;
7. Identify relevant targets and new therapeutic approaches for cellular therapy in solid tumor malignancies;
8. Consider current strategies using cellular therapy for the treatment of non-malignant conditions;
9. Assess new strategies in the cellular therapy research including targeting neo-antigens.

CONFERENCE LOCATION

IN-PERSON:

University of Chicago
David Rubenstein Forum,
1201 E. 60th St. Chicago, IL 60637

VIRTUAL:

Log in information will be sent to registrants 72 hours prior to the conference.

8:00 am REGISTRATION AND BREAKFAST

8:50 am WELCOME AND INTRODUCTIONS

Peter Riedell, MD
University of Chicago Medicine

Michael Bishop, MD
University of Chicago Medicine

OPTIMIZING CELLULAR THERAPY MANUFACTURING

Moderator: Richard Koya, MD, PhD
University of Chicago Medicine

9:00 am CAR T-Cell Manufacturing in the Academic Setting

Isabelle Riviere, PhD
Memorial Sloan Kettering
Cancer Center

9:20 am Point of Care Cell Manufacturing - Rewards and Challenges

Amittha Wickrema, PhD
University of Chicago Medicine

MECHANISMS OF RESISTANCE AND RELAPSE TO CELLULAR THERAPY

Moderator: Justin Kline, MD
University of Chicago Medicine

9:40 am Genomic Drivers of Resistance to Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-cell Lymphoma

Jonathan Schatz, MD
University of Miami

10:00 am Developmental Trajectories of CAR-Driven T-Cell Failure

Nathan Singh, MD
Washington University in St. Louis

10:20 am Mechanisms of Resistance to CD19-Targeted CAR T-Cell Therapies

Marco Davila, MD, PhD
Moffitt Cancer Center

10:40 am BREAK

CELLULAR THERAPY IN NON-MALIGNANT DISEASES

Moderator: James LaBelle, MD, PhD
University of Chicago Medicine

11:00 am Therapeutic Gene Editing for Sickle Cell Disease

Daniel Bauer, MD, PhD
Dana-Farber Cancer Institute/
Boston Children's Hospital

11:20 am HIV CAR T-Cells for HIV Cure Studies

James L. Riley, PhD
University of Pennsylvania

11:40 am LUNCH

CELLULAR THERAPY IN SOLID TUMORS

Moderator: Michael Bishop, MD
University of Chicago Medicine

12:40 pm CAR T-Cells from Bench to Clinical Application

Gianpietro Dotti, MD
University of North Carolina

1:00 pm High-Precision, High-Throughput Cell Profiling for Autologous Cell Therapy Development

Shana Kelley, PhD
Northwestern University

LIGHTENING TALKS

Moderator: Stephen Kron, MD, PhD
University of Chicago Medicine

1:20 pm Two-Stage CD28-Costimulated CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma

Yifei Hu, BA
University of Chicago Medicine

1:35 pm BCL-2 Inhibition Mediates Treg to TH17 Plasticity

Rosy Liao
University of Chicago Medicine

1:50 pm TCR T-Cell Therapy Targeting Solid Tumors

Steven Wolf, PhD
University of Chicago Medicine

2:05 pm Investigational New Drug (IND) Enabling Validation of Tri-specific CD19/20/22 CAR T-Cells for Point of Care Manufacturing

Mahzad Akbarpour, PhD
University of Chicago Medicine

2:20 pm BREAK

2:40 pm Janet Rowley Lecture
Developing Cellular Therapies Against GD2: It Doesn't Hurt!

Christian Capitini, MD
University of Wisconsin

3:10 pm Jonas Memorial Lecture
Development of Cancer-Specific TCR Gene Therapy

Hans Schreiber, MD, PhD
University of Chicago Medicine

4:10 pm CLOSING REMARKS

Michael Bishop, MD
University of Chicago Medicine

4:15 pm ADJOURN

